‡a
Author's Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial
‡a
safetyandclinicalactivityofanewantipdl1antibodyasmonotherapyorcombinedwithtargetedtherapyinadvancedsolidtumorsthepactphaseiaibtrial
‡A
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial
‡9
1